Pharmaceutical Stock Bounces Off Record Lows

Kenvue (KVUE) stock initially gapped lower following a Trump administration statement linking acetaminophen use in pregnancy to autism, a claim medical professionals widely dispute. While KVUE is up 3.9% today to $17.62, recovering some losses, it remains 7.5% below its pre-gap level and 23.3% down year-over-year. Options market sentiment reflects heightened bearishness, with a significantly elevated 50-day put/call volume ratio and today's trading volume six times the average, including notable activity in weekly 10/3 17.50-strike puts.

Analysis

Kenvue Inc. (KVUE) experienced significant volatility after a statement from the Trump administration linking acetaminophen, the active ingredient in its Tylenol product, to autism. This catalyst triggered a 7.5% bear gap and pushed the stock to a record low of $16.89. Although medical professionals have criticized the claim for lacking scientific evidence, leading to a subsequent 3.9% rebound to $17.62, the stock remains well below its pre-gap levels and its 20-day moving average. The longer-term technical picture is weak, with the stock carrying a 23.3% year-over-year deficit. Options market activity underscores the heightened uncertainty and bearish sentiment. While call volume outpaces put volume in absolute terms for the day, the 50-day put/call volume ratio across major exchanges now ranks in the 90th percentile of its annual range, signaling a dramatic increase in bearish or protective positioning. This is further substantiated by total options volume running at six times the typical rate and new positions being opened in near-term weekly puts at the 17.50-strike price.

Key Decisions for Investors

• Given the elevated put/call ratio and extreme options volume, investors should anticipate continued price volatility and monitor the weekly 10/3 17.50-strike put activity as a potential indicator of near-term support or resistance.
• The 3.9% rebound off a record low, fueled by a catalyst that medical experts dispute, may present a high-risk, tactical opportunity for contrarian investors, as suggested by the high volume in out-of-the-money November call contracts.
• Long-term investors should consider that the stock's 23.3% year-over-year decline indicates fundamental weakness predating this headline risk, warranting caution until the potential for lasting brand damage to Tylenol can be more accurately assessed.